ClinicalTrials.gov
ClinicalTrials.gov Menu

Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01121068
Recruitment Status : Completed
First Posted : May 12, 2010
Last Update Posted : January 6, 2014
Sponsor:
Information provided by (Responsible Party):
Jae-Joon Yim, Seoul National University Hospital

Brief Summary:
Interferon gamma releasing assay(IGRA) is useful to diagnose latent tuberculosis. However,IGRA responses could show within-subject variability. We wanted to determine long-term IGRA variability in health-care workers who continuously expose to tuberculosis patients.

Condition or disease Intervention/treatment
Tuberculosis Other: Blood samplings

Detailed Description:
IGRA will be performed monthly in health-care workers with continuous exposure to tuberculosis patients for 1 year.

Study Type : Observational
Actual Enrollment : 49 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Monthly Follow up of Interferon Gamma Releasing Assay Among Health-care Workers Treating TB Patients
Study Start Date : May 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis
Drug Information available for: Interferon

Group/Cohort Intervention/treatment
Health care workers Other: Blood samplings
About 3.5ml of blood will be drawn from the participants monthly.




Primary Outcome Measures :
  1. Results of interferon-gamma releasing assay [ Time Frame: monthly for 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Health care workers who are continuously exposed to TB patients
Criteria

Inclusion Criteria:

  • Health care workers who are continuously exposed to TB patients Age > 20 years

Exclusion Criteria:

  • Pregnant Active TB Use of immunosuppressants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01121068


Locations
Korea, Republic of
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Study Chair: Jae-Joon Yim, MD Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jae-Joon Yim, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01121068     History of Changes
Other Study ID Numbers: monthly IGRA
First Posted: May 12, 2010    Key Record Dates
Last Update Posted: January 6, 2014
Last Verified: January 2014

Keywords provided by Jae-Joon Yim, Seoul National University Hospital:
IGRA
variability
Long-term variability of IGRA

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Interferons
Interferon-gamma
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents